Sachdeva Kuldeep Singh, Chadha Vineet K
Molbio Diagnostics, Verna, Goa, India.
Epidemiology and Research Division, National Tuberculosis Institute, Bengaluru, Karnataka, India.
Indian J Med Res. 2024;160(3&4):338-345. doi: 10.25259/IJMR_1478_2024.
Tuberculosis continues to be among the leading causes of morbidity as well as mortality. It is appreciated that our aim of eliminating TB in the foreseeable future will not be realized until we have a new vaccine with significant efficacy among diverse populations and all age-groups. Although impressive strides have been made in more refined development of new TB vaccines based on learnings from past experiences, the substitute or a booster vaccine for the BCG vaccine is not available yet. This article puts in perspective the recent efforts in re-positioning BCG, development of newer vaccines based on novel approaches, the current TB vaccine pipeline, yet unmet challenges in vaccine development, exploring newer ideas in vaccine development and what the future holds.
结核病仍然是发病和死亡的主要原因之一。人们认识到，在可预见的未来，除非我们拥有一种在不同人群和所有年龄组中都具有显著疗效的新型疫苗，否则消除结核病的目标将无法实现。尽管基于过去的经验教训，新型结核病疫苗的研发取得了令人瞩目的进展，但卡介苗的替代疫苗或加强疫苗尚未问世。本文阐述了重新定位卡介苗的近期努力、基于新方法开发新型疫苗、当前结核病疫苗研发进展、疫苗开发中尚未解决的挑战、探索疫苗开发的新思路以及未来的发展方向。
